Stryker Corporation

The forensic scores point in a mostly reassuring direction, and each should be read against its label. The Beneish M-Score is -2.622, which is below -1.78 and therefore not in the elevated manipulation-risk zone; that is a screening result, not a finding either way. The Altman Z″-Score is 3.96, in the safe zone, meaning the model's balance-sheet indicators do not signal distress. The Piotroski F-Score is 6 of 8 computable signals, meaning six of the eight checks the data could support were passed and the rest could not be computed. Operating cash flow of $5.04 billion against net income of $3.25 billion gives a ratio of 1.55 for 2025, which suggests reported profits are backed by cash. Against that, the 10-Q and 10-K text describe several items that deserve a closer read: tariffs struck down in Learning Resources, Inc. v. Trump may bring refunds whose timing and amount are uncertain, while new Section 122 tariffs could raise costs; the Orthopaedics segment reported Spinal Implants 2 sales of $2 million against $166 million a year earlier; and the Ortho Tech reorganization changes how segments are presented, so comparisons should use the recast figures. Readers may want to look at the risk factors on pricing pressure from China's volume-based procurement and on sole-source suppliers, which the 10-K says could halt specific products. The balance sheet shows liabilities of $25.42 billion against equity of $22.42 billion at 2025 year-end, so leverage is rising as debt grows.

Catalyst.According to the 10-Q for the quarter ended 2026-03-31, net sales rose 2.6% to $6,020 million from $5,866 million, with 1.0% growth in constant currency. Management points to Vascular, whose sales grew 27.5% to $517 million, and Trauma and Extremities, up 9.5% to $1,035 million. Net earnings were $745 million versus $654 million, and the company reorganized parts of its orthopaedic business into a new Ortho Tech unit while stating that its capital allocation priorities remain acquisitions, dividends and share repurchases. Full-year 2025 revenue reached $25.12 billion, up 11.2% from $22.59 billion in 2024.

Hidden risk.The cybersecurity incident identified in the first quarter of 2026 disrupted operations, and management attributes the gross margin decline to idle production time it caused, with manufacturing and supply chain costs a 200 basis point drag. The investigation remains ongoing, so the full financial effect is not yet known. Adjusted operating margin fell 180 basis points to 21.1% and adjusted EPS fell 8.5% to $2.60, even as GAAP net earnings rose 13.9%, so the gap between GAAP and adjusted results is worth reading closely. Long-term debt climbed to $14.86 billion at 2025 year-end from $12.19 billion, and quarterly interest expense rose to $148 million from $137 million.